377 Hyperthyroidism

Question 1

Smoking is a minor risk factor for the development of Graves disease but is a major risk factor for developing this clinical manifestation (H20 C377 P2703)

Answer 1

Ophthalmopathy

Question 2

In the elderly, features of thyrotoxicosis may be subtle or masked, and patients may present mainly with fatigue and weight loss, a condition known as: (H20 C377 P2703)

Answer 2

Apathetic thyrotoxicosis

Question 3

Most common symptoms [3] of Graves disease (H20 C377 P2703)

Answer 3

Hyperactivity, irritability, dysphoria

Question 4

Most common sign of Graves disease (H20 C377 P2703)

Answer 4

Tachycardia

Question 5

Thyrotoxicosis is sometimes associated with a form of hypokalemic periodic paralysis; this disorder is particularly common in: (H20 C377 P2704)

Answer 5

Asian males

Question 6

The most common cardiovascular manifestation of Graves disease is: (H20 C377 P2704)

Answer 6

Sinus tachycardia

Question 7

Atrial fibrillation in Graves disease is more common in patients age: (H20 C377 P2704)

Answer 7

> 50 years

Question 8

The most serious manifestation of Graves opthalmopathy (H20 C377 P2704)

Answer 8

Compression of the optic nerve

Question 9

Thyroid dermopathy is almost always occurs in the presence of: (H20 C377 P2704)

Answer 9

Moderate to severe ophthalmopathy

Question 10

Thyroid acropachy is strongly associated with this clinical manifestation (H20 C377 P2704)

Answer 10

Thyroid dermopathy

Question 11

Imaging test that may distinguish between hyper- thyroidism and destructive thyroiditis. (H20 C377 P2705)

Answer 11

Color-flow Doppler ultrasonography

Question 12

Half-life of methimazole (H20 C377 P2706)

Answer 12

6 h

Question 13

Half-life of propylthiouracil (H20 C377 P2706)

Answer 13

90 min

Question 14

Usual initial dose of methimazole or carbimazole in Graves disease (H20 C377 P2706)

Answer 14

10-20 mg q 8-12 h

Question 15

Usual initial dose of PTU in Graves disease (H20 C377 P2706)

Answer 15

100-200 mg q 6-8 h

Question 16

TFTs and clinical manifestations are reviewed how long after initiation of thionamides? (H20 C377 P2706)

Answer 16

4-6 weeks

Question 17

Maximum remission rates of medically treated Graves disease is achieved by how many months? (H20 C377 P2706)

Answer 17

12-18 months

Question 18

Carbimazole or methimazole must be stopped how many days before RAI? When can it be restarted? (H20 C377 P2706)

Answer 18

2-3 days before, 3-7 days after

Question 19

Hyperthyroidism can persist for how long before RAI takes full effect? (H20 C377 P2706)

Answer 19

2-3 months

Question 20

Drug that is given prior to total or near total thyroidectomy for Graves disease to avoid thyrotoxic crisis and to reduce vascularity of the gland (H20 C377 P2707)

Answer 20

SSKI

Question 21

PTU should be used in pregnant women until how many weeks gestation? (H20 C377 P2707)

Answer 21

14-16 weeks

Question 22

High levels of maternal TSI at how many weeks gestation are associated with fetal or neonatal thyrotoxicosis (H20 C377 P2707)

Answer 22

26 weeks

Question 23

Some authorities advocate supplementation with this drug to reduce Graves ophthalmopathy (H20 C377 P2707)

Answer 23

Selenium 100 mcg BID

Question 24

Most common cause of acute thyroiditis in children and young adults (H20 C377 P2708)

Answer 24

Presence of a pyriform sinus

Question 25

Diagnostic test that may be useful in distinguishing unilateral involvement of subacute thyroiditis from bleeding into a cyst or neoplasm (H20 C377 P2709)

Answer 25

FNA biopsy

Question 26

Subacute thyroiditis evolve through three phases over this duration (H20 C377 P2708)

Answer 26

6 months

Question 27

Silent thyroiditis is associated with the presence of TPO antibodies antepartum, and it is three times more common in women with: (H20 C377 P2709)

Answer 27

Type 1 diabetes mellitus

Question 28

The most common clinically apparent cause of chronic thyroiditis (H20 C377 P2709)

Answer 28

Hashimoto thyroiditis

Question 29

Aside from surgery, this treatment may be beneficial in Riedel thyroiditis (H20 C377 P2709)

Answer 29

Tamoxifen

Question 30

Most common hormone pattern in sick euthyroid syndrome (H20 C377 P2709)

Answer 30

Low T3 syndrome

Question 31

Iodine content of amiodarone by weight (H20 C377 P2710)

Answer 31

39%

Question 32

High iodine levels persist for how long after discontinuation of amiodarone (H20 C377 P2710)

Answer 32

> 6 months

Question 33

Type of amiodarone-induced thyrotoxicosis in patients with underlying thyroid abnormalities (H20 C377 P2710)

Answer 33

Type 1 AIT

Question 34

Diagnostic test that can distinguish between type 1 and type 2 AIT (H20 C377 P2710)

Answer 34

Color-flow Doppler ultrasonography

Increased vascularity in type 1, decreased vascularity in type 2 AIT

Question 35

Serious adverse effect of potassium perchlorate therapy (H20 C377 P2710)

Answer 35

Agranulocytosis